GlassScriptPhysician profile
Alexia R Rowley
NPI 1588085930
$4,099.80
in general payments reported to CMS, 2019-2025
26 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $163 · 2023: $420 · 2024: $792 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771 · Consulting Fee: $630 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.11 |
| Consulting Fee | $630.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $973.01 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $603.46 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $498.19 | 2021-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.73 | 2021-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $193.70 | 2022-2025 | Fasenra, Breztri, Tezspire |
| Insmed, INC. | $153.64 | 2024-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $125.00 | 2022 | |
| Mylan Specialty L.P. | $124.53 | 2023-2024 | Yupelri |
| United Therapeutics Corporation | $91.64 | 2023-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.39 | 2024-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $83.44 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $70.82 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $63.03 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $56.95 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $53.24 | 2024-2025 | Inspire |
| Pinnacle Biologics, INC | $50.75 | 2024 | Photofrin |
| Verona Pharma, INC. | $48.08 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $46.98 | 2021 | |
| Inogen, INC. | $37.55 | 2025 | |
| Electromed, INC. | $35.64 | 2021 | |
| Viatris Specialty LLC | $30.12 | 2025 | Yupelri |
| 3b Medical, INC. | $29.03 | 2024 | Luna |
| Alcresta Therapeutics, INC. | $24.92 | 2025 | Relizorb |
| Grifols USA, LLC | $20.51 | 2024 | Prolastin-C Liquid |
| Philips North America LLC | $14.46 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Rowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.